AZ505

Research use only, not for human use.

AZ505 (AZ-505, AZ 505) is a potent and selective inhibitor of protein lysine methyltransferase SMYD2 with IC50 of 0.12 uM.

AZ505 (AZ-505, AZ 505) is a potent and selective inhibitor of protein lysine methyltransferase SMYD2 with IC50 of 0.12 uM, displays >600-fold against other histone methyltransferases, such as SMYD3 and EZH2; suppresses BMP2-induced SMAD1/5 phosphorylation, delays cyst growth in both early- and later-stage Pkd1 conditional knockout mouse models; also significantly reduced tumor growth in vivo in triple-negative breast cancer (TNBC) models.

AZ-505;AZ 505

Chromatin/Epigenetic

HMTase

HMTase

Cancer

——

1035227-43-0

577.54

C29H38Cl2N4O4

>98% (HPLC)

DMSO : ≥ 42 mg/mL72.72 mM

C1CCC(CC1)N(CCNCCC2=C3C(=C(C=C2)O)NC(=O)CO3)C(=O)CCNCCC4=CC(=C(C=C4)Cl)Cl

Propanamide, N-cyclohexyl-3-[[2-(3,4-dichlorophenyl)ethyl]amino]-N-[2-[[2-(3,4-dihydro-5-hydroxy-3-oxo-2H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]-

(-20℃)

With Ice Pack

≥ 2 years